EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of a new ELISA for fully automated detection of anti-GAD autoantibodies in type 1 diabetes and anti-GAD-associated neurological diseases

Gia-Gia Toni Hò, Martina Lehmann, Petra Augstein, Malgorzata Baranowska-Dell, Cornelia Dähnrich, Andrea Deerberg, Sandra Saschenbrecker, Wolfgang Kerner, Lars Komorowski, Alexander Kühnl, Kai Masur, Christian Probst und 3 weitere

Clinica Chimica Acta · 2026-11 · 122976

DOI: 10.1016/j.cca.2026.122976 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinica Chimica Acta, 2026-11. Verfasst von Gia-Gia Toni Hò und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany. Electronic address: g.ho@uni-luebec…. Die Arbeit nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoantibodies against glutamic acid decarboxylase (GAD) support diagnostics and classification of type 1 diabetes (T1D) and anti-GAD antibody-associated neurological diseases. This study evaluated the analytical and clinical performance of the newly developed, IVDR-compliant Euroimmun Anti-GAD ELISA, which is based on a bridge format and enables fully automated sample processing. Analytical assessment included precision, interference, and linearity. Clinical performance and comparison with the predecessor ELISA and the Medipan CentAK anti-GAD M radioimmunoassay (RIA) were examined using sera from patients with T1D (median age at diagnosis: 11 years; median diabetes duration: 4 years), stiff-person spectrum and other neurological conditions, latent autoimmune diabetes in adults, Addison's disease, various non-T1D control groups, and samples from the Islet Autoantibody Standardization Program (IASP). The new ELISA demonstrated excellent analytical characteristics (intra-/inter-lot CV ≤ 6%), linearity (5-2000 IU/mL), and no interference from hemolysis, lipemia, or bilirubin. Diagnostic sensitivity reached 59.9% in the clinical T1D cohort (newly diagnosed T1D: 73.9%) and 84.0% in IASP samples, with a specificity of 97.3%. Diagnostic sensitivity for anti-GAD antibody-associated neurological diseases was 74.8%. Concordance with the predecessor ELISA was almost perfect (98.7%, κ = 0.968) and was supported by strong quantitative correlation. Comparison with the RIA showed substantial agreement (83.3-84.7%, κ ≈ 0.7) and higher sensitivity of the ELISA, detecting additional, predominantly low-level-positive T1D samples. In conclusion, the new Euroimmun Anti-GAD ELISA provides strong analytical and diagnostic performance for T1D and anti-GAD antibody-associated neurological diseases. Its rapid, fully automated format supports efficient high-throughput testing for routine diagnostics and population-based screening. Parallel testing for multiple pancreatic islet autoantibodies may enhance diagnostic coverage and aid clinical decision-making.

Schlagwörter

Stichwörter der Autor:innen

Anti-GAD autoantibodiesBiomarkerELISAFully automatedScreeningStiff-person spectrum disordersType 1 diabetes

Autor:innen und Institutionen

  • Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany. Electronic address: g.ho@uni-luebeck.de.
  • Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany. Electronic address: martina.lehmann@revvity.com.
  • Department for Diabetology, Klinikum Karlsburg, Heart and Diabetes Center Karlsburg, Germany. Electronic address: augsteinp@drguth.de.
  • Department of General, Visceral, Thoracic, and Vascular Surgery, Research Group of Predictive Diagnostics, University Medical Center Greifswald, Germany. Electronic address: m.baranowska@herrdell.de.
  • Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany.
  • Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany. Electronic address: andrea.deerberg@revvity.com.

Förderung

  • European Regional Development Fund

Zitieren

APA

Hò, G. T., Lehmann, M., Augstein, P., Baranowska-Dell, M., Dähnrich, C., Deerberg, A., Saschenbrecker, S., Kerner, W., Komorowski, L., Kühnl, A., Masur, K., Probst, C., Rhein, S., Schlosser, M., & Elleuche, S. (2026). Evaluation of a new ELISA for fully automated detection of anti-GAD autoantibodies in type 1 diabetes and anti-GAD-associated neurological diseases. Clinica Chimica Acta, 122976. https://doi.org/10.1016/j.cca.2026.122976

Vancouver

Hò GT, Lehmann M, Augstein P, Baranowska-Dell M, Dähnrich C, Deerberg A, et al. Evaluation of a new ELISA for fully automated detection of anti-GAD autoantibodies in type 1 diabetes and anti-GAD-associated neurological diseases. Clinica Chimica Acta. 2026:122976. doi:10.1016/j.cca.2026.122976

BibTeX
@article{H2026,
  author = {Hò, Gia-Gia Toni and Lehmann, Martina and Augstein, Petra and Baranowska-Dell, Malgorzata and Dähnrich, Cornelia and Deerberg, Andrea and Saschenbrecker, Sandra and Kerner, Wolfgang and Komorowski, Lars and Kühnl, Alexander and Masur, Kai and Probst, Christian and Rhein, Sina and Schlosser, Michael and Elleuche, Skander},
  title = {Evaluation of a new ELISA for fully automated detection of anti-GAD autoantibodies in type 1 diabetes and anti-GAD-associated neurological diseases},
  journal = {Clinica Chimica Acta},
  year = {2026},
  pages = {122976},
  doi = {10.1016/j.cca.2026.122976}
}
Kostenlos starten →